Antimicrobial activity and spectrum of SCH27899 (Ziracin(®)) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control

Diagnostic Microbiology and Infectious Disease

Volumn 34, Issue 2, 1999, Pages 103-110

  Jones, Ronald N ^a   Marshall, Steven A ^a   Erwin, Meredith E ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF IOWA   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^e (C Knapp)   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; EVERNIMICIN; GENTAMICIN; PENICILLIN G; STREPTOMYCIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AGAR GEL DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; REFERENCE STANDARDS;

EID: 0032973163     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00093-5     Document Type: Article

References (15)

1. Aarestrup F.M. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microbial Drug Res. 4:1998;137-141.
2. Black J., Calesnick B., Falco F.G., Weinstein M.J. Pharmacological properties of everninomicin D. Antimicrob Agents Chemother. 0:1964;38-46.
3. Cormican M.G., Marshall S.A., Jones R.N. Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents. Diagn Microbiol Infect Dis. 23:1995;157-160.
4. Ganguly A.K., Girijavallabhan V.M., Miller G.H., Sarre O.Z. Chemical modification of everninomicin. J Antibiot. 35:1982;561-570.
5. Gavan T.L., Jones R.N., Barry A.L., Fuchs P.C., Gerlach E.H., Matsen J.M., Reller L.B., Thornsberry C., Thrupp L.D. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests A collaborative study . J Clin Microbiol. 14:1981;67-72.
6. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
7. Jones R.N., Barrett M.S. Antimicrobial activity of everninomicin (SCH 27899), an oligosaccharide antimicrobial with a potent Gram-positive spectrum. Clin Microbiol Infect. 1:1995;35-43.
8. Nakashio S., Iwasawa H., Don F.Y., Kanemitso K., Shimada I. Everninomicin, a new oligosaccharide antibiotic Its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity . Drugs Exptl Clin Res. 1:1995;7-16.
9. Performance standards for antimicrobial disk susceptibility tests, 6th ed. Approved standard M2-A6. 1997;National Committee for Clinical Laboratory Standard, Wayne, PA.
10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. 1997;NCCLS, Wayne, PA.
11. Performance standards for antimicrobial susceptibility testing, Eighth information suppl M100-S8. 1998;NCCLS, Wayne, PA.
12. Development of in vitro susceptibility testing criteria and quality control parameters, tentative guideline M23-T3. 1998;NCCLS, Wayne, PA.
13. Sanders W.E. Jr, Sanders C.C. Microbiological characterization of everninomicin B and D. Antimicrob Agents Chemother. 6:1974;232-238.
14. Urban C., Mariano N., Mosinka-Snipas K., Wadee C., Chahrour T., Rahal J.J. Comparative in vitro activity of SCH-27899, a novel everninomicin, and vancomycin. J Antimicrob Chemother. 37:1996;361-364.
15. Weinstein MJ, Luedemann GM, Oden EM, and Wagman GH (1964) Everninomicin, a new antibiotic complex from Micromonospora carbonacea. Antimicrob Agents Chemother 24-32.